Overview

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of PF-06882961 in Chinese Adults With Type 2 Diabetes Mellitus

Status:
Recruiting
Trial end date:
2022-01-23
Target enrollment:
Participant gender:
Summary
This is a Phase 1, randomized, double-blind (sponsor open), placebo controlled study in adult Chinese participants with T2DM who are receiving metformin as background antihyperglycemic medication.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer